MedWatch

Genmab ditches drug candidate

The biotech firm genmab shelves cancer project which US J.P. Morgen predicted would have sales potential at USD 2bn per year.

Photo: Lars Møller / Genmab / PR

The Danish biotech firm Genmab has lost a potential blockbuster drug. Genmab has decided to ditch the drug candidate enapotamab vedotin for treating cancer, which the firm announces in a statement.

"We are committed to developing innovative antibody products for patients with cancer, however the data from the enapotamab vedotin expansion cohorts unfortunately does not support moving this product candidate forward," states CEO Jan van de Winkel in the press announcement.

Read this article for free

Register with your E-mail.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

Related articles